NEW YORK, May 11, 2015 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE:AMPE).
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that (1) the clinical research organization conducting the STEP Study lacked autonomy; and (2) the trial drug supply for the STEP Study was shipped to clinical sites at lower temperatures than were permitted by the drug's specifications.
On April 20, 2015, Ampio announced that "the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control test." On this news, shares of Ampio fell $5.18 per share, to close at $2.69, or more than 65.8%, on April 24, 2015.
Request more information now by clicking here: www.faruqilaw.com/AMPE. There is no cost or obligation to you.
Take Action
If you invested in Ampio stock or options between January 13, 2014 through August 21, 2014 and would like to discuss your legal rights, visit www.faruqilaw.com/AMPE. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding Ampio's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330
Logo - http://photos.prnewswire.com/prnh/20120119/MM38856LOGO
SOURCE Faruqi & Faruqi, LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article